CA
NZ
UK
AU
IND
US
The company began Nasdaq trading in late October 2026 after completing itsMergerwith a blank-check company. It develops atomic layer deposition equipment used on semiconductor wafers, filters, membranes and battery materials. At under USD 5 it is a penny stock, with a 52-week range of …
A prospectus supplement dated July 14, 2026 allows sales of up to USD 3.95 million of common stock through an at-the-market program, with no minimum sale required. Cash was approximately USD 1.0 million at fiscal year end, and the shares are now below USD …
The company said no other products are affected and that it is working with the FDA. It did not disclose a financial impact. A business update call was set for 8:30 a.m. ET on November 2, 2026, and third quarter fiscal 2026 results are …
In a press release dated October 29, 2026, the electric motorcycle maker reported third quarter revenue of USD 7.9 million, withdrew its 2026 operating loss guidance and disclosed substantial doubt about its ability to continue as a going concern. Cash was USD 39.9 million …
RoboticsRevenuewas about USD 12,000 in the fiscal year ended March 31, 2026, so the contract is several times that figure, though it is recognized over time (calculated comparison, based on company figures). As a penny stock, it can swing sharply on smallVolumeand may rely …
A NEAR governance vote on proposal HSP-029 closed on November 2, 2026, which would cut the maximum annual issuance rate from 2.5 percent to 1.6 percent. This is context rather than a confirmed cause. The company holds more than 55.5 million NEAR, has not …
The cited ground is a closing bid price below USD 1.00 for 30 consecutiveBusinessdays. The company is not eligible for a compliance period because it completed a 1-for-25 reverse split on March 16, 2026. It intends to request a hearing by November 3, 2026, …
Management said the recovery is taking longer than anticipated and expects gradual improvement from the fourth quarter. Security subscriptions revenue rose 11 percent to USD 338.6 million. The call was scheduled for 8:30 AM ET.
A release dated October 6, 2026 reported fiscal 2026 annualRecurring Revenuesales of USD 2.2 million from 75 sales for its HawkSearch platform. Cash was approximately USD 1.0 million, and a USD 3.95 million at-the-market offering was set up on July 14, 2026. As a …
The company markets the oral cancer drug XPOVIO. Fiscal 2025 revenue was USD 146.1 million with a net loss of USD 196.0 million. Its notes carry conversion rights that could dilute shareholders, and no filing describing the outcome after November 1, 2026 was found. …
Please wait processing your request...